Home > Maligne hematologie > Myeloïde ziekten > Myelodysplastisch syndroom > SAR443579 – TCD17197

SAR443579 – TCD17197

An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high riskmyelodysplasia (HR-MDS)

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 21:05